Ticker
IMRX
Analysis
Immuneering Corporation (IMRX) Stock Analysis
Immuneering Corporation investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to IMRX.
Immuneering Corporation
Immuneering Corporation investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to IMRX.
Stock profile
Asset type
Stock
Market cap
$285.3M
Sector
Health Technology
Industry
Pharmaceuticals: Major
Currency
USD
Ticker listings
Immuneering Corporation may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.
- IMRX primary listing
Latest Immuneering Corporation news
Immuneering Appoints Andrew Gengos as Chief Financial Officer
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 ...
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-L...
- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categ...
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plu...
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual...
Research sections
Valuation
Review valuation context for Immuneering Corporation.
Future growth
Review future growth context for Immuneering Corporation.
Past performance
Review past performance context for Immuneering Corporation.
Financial health
Review financial health context for Immuneering Corporation.
Dividend
Review dividend context for Immuneering Corporation.
Management
Review management context for Immuneering Corporation.
Ownership
Review ownership context for Immuneering Corporation.
Other information
Review other information context for Immuneering Corporation.
Community
Review community context for Immuneering Corporation.